Ankit Parikh, MD
Infectious Disease · Camp Hill, PANPI 1932477833
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $768 of the $893 with a category attached, or 86.0%. It is spread thinly across 13 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations.
Across 43 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$167
- AbbVie$134
- Paratek Pharmaceuticals, Inc.$113
- Melinta Therapeutics, LLC$86
- Aimmune Therapeutics, Inc.$78
- Insmed, Inc.$75
- plus $242 from 7 others
What the payments were for
- Food & beverage$76886%
- Education$12514%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 5 | $167 |
| AbbVie | 7 | $134 |
| Paratek Pharmaceuticals, Inc. | 7 | $113 |
| Melinta Therapeutics, LLC | 4 | $86 |
| Aimmune Therapeutics, Inc. | 4 | $78 |
| Insmed, Inc. | 3 | $75 |
| Viiv Healthcare Company | 4 | $67 |
| Gilead | 3 | $58 |
| Ferring Pharmaceuticals Inc. | 1 | $39 |
| Cumberland Pharmaceuticals, Inc. | 2 | $34 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $16 |
| Theratechnologies Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
How this compares
$893 in reported general payments places this provider in the 75th percentile of 457 infectious disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 43 | $94,564 |
| Meropenem | 73 | $20,260 |
| Cefepime Hcl | 49 | $15,750 |
| CeftriaxoneCeftriaxone Sodium | 49 | $7,795 |
| Vancomycin Hcl | 42 | $6,634 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 15 | $3,190 |
| Cefazolin Sodium | 28 | $1,079 |
| Cefdinir | 26 | $941 |
| Doxycycline Monohydrate | 17 | $838 |
| Doxycycline Hyclate | 14 | $527 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Camp Hill
- David HornPhiladelphia$2.1M
- Judith WolfPhiladelphia$1.2M
- Karam MounzerPhiladelphia$712K
- William ShortPhiladelphia$520K
- David WuWest Chester$483K
- William PaceSouthampton$472K
- Amesh AdaljaPittsburgh$415K
- Brett GilbertWynnewood$352K
- Timothy BabinchakPhoenixville$311K
- Tuesdae Stainbrookdu Bois$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.